Abstract:BACKGROUND:Existing research shows that ABT-199, as a first-line drug, have been widely used in hematological malignancies, especially in leukemia, but the clinical efficacy of single drug therapy was limited part of the reason was that BCL-2 inhibitors failure to target other anti-apoptotic BCL-2 family proteins, such as MCL-1. In this case, combination therapy may be a promising way to overcome this obstacle. Here, we investigate the preclinical efficacy of a new strategy combining ABT-199 with homoharringtonine (HHT), a selective inhibitor of MCL-1 may be a promising approach for AML treatment as these two molecules are important in apoptosis.METHODS:A Cell Counting Kit-8 (CCK8) assay and flow cytometry were used to determine the half-maximal inhibitory concentration (IC50) value and cell apoptosis rate, respectively. The flow cytometry results showed that combined treatment with HHT and ABT-199 caused apoptosis in AML patient samples (n=5) but had no effect on normal healthy donor samples (n=11). Furthermore, we used a Western blot assay to explore the mechanism underlying the efficacy of HHT combined with ABT-199. Finally, antileukemic activity was further evaluated in vivo xenograft model.RESULTS:Our results indicated that ABT-199 combined with HHT significantly inhibited cell growth and promoted apoptosis in both AML cell lines and primary AML tumors in a dose- and time-dependent manner. Moreover, HHT combined with ABT-199 suppressed AML cell growth and progression in vivo xenograft model.CONCLUSIONS:Our research found that HHT combined with ABT-199 exerted its anti-leukemia effect by inducing apoptosis through the treatment of AML in vitro and in vivo.

[Comparative Proteomics Research of Apoptosis Initiation Induced by Homoharringtonine in HL-60 Cells].

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.

Homoharringtonine Affects the Jak2-Stat5 Signal Pathway Through Alteration of Protein Tyrosine Kinase Phosphorylation in Acute Myeloid Leukemia Cells

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.

Homoharringtonine Binds to and Increases Myosin-9 in Myeloid Leukaemia.

[Effect of Homoharringtonine Combined with AG490 on JAK2-STAT5 Associated Signal Pathway in HEL Cells].

Homoharringtonine combined with BRD4 inhibitor JQ1 induces apoptosis of acute myeloid leukemia cells

Apoptosis of HL-60 Cells Induced by Dihydroartemisinin

Interferon-α in Combination with Homoharringtonine Induces K562 Cell Apoptosis Through Down-Regulating Human Telomerase Reverse Transcriptase Expression and Telomerase Activity

Gene Expression Profiling in Apoptotic K562 Cells Treated by Homoharringtonine

Homoharringtonine Inhibits the Akt Pathway and Induces in Vitro and in Vivo Cytotoxicity in Human Multiple Myeloma Cells

Homoharringtonine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of telomerase.

Gene Expression Pattern in Apoptotic QGY-7703 Cells Induced by Homoharringtonine

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia.

Homoharringtonine is Synergistically Lethal with BCL-2 Inhibitor APG-2575 in Acute Myeloid Leukemia

Harmine Induces Apoptosis in Human SGC-7901 Cells

Inhibition Effect of Homoharringtonine on Telomerase Activity of K562 Cells

Effect and Possible Mechanism of Tripterine on Inducing Apoptosis of Human Acute Myelocytic Leukemia HL-60 Cells.

Mechanism of Apoptotic Induction on T24 Cells by Honokiol and Its Synergistic Anticancer Effect in Combination with Hydroxycamptothecin

Harringtonine Induces Apoptosis in NB4 Cells Through Down-Regulation of Mcl-1